Scholar Rock (SRRK)

Executive Summary

Scholar Rock is a biopharmaceutical company focused on developing innovative therapies that target the TGFβ superfamily, with a lead candidate apitegromab (SRK-015) for spinal muscular atrophy (SMA). The company leverages its proprietary platform to design potent and selective inhibitors of latent TGFβ activation, aiming to address significant unmet needs in neuromuscular and oncologic diseases. In 2025, Scholar Rock reported positive Phase 2 results for apitegromab in Type 2 and Type 3 SMA, demonstrating sustained motor function improvements. The subsequent Phase 3 TOPAZ trial is fully enrolled with data expected in mid-2026. A successful readout could position apitegromab as a first-in-class therapy for SMA, potentially expanding the treatment landscape beyond SMN2-targeting drugs. Beyond SMA, Scholar Rock is advancing early-stage programs in oncology, including SRK-439 in myelofibrosis and other fibrosis indications. The company maintains a strong balance sheet with sufficient cash runway into 2027, supporting key catalysts. However, the stock has faced volatility due to mixed investor sentiment around SMA market dynamics and competition. Key risks include regulatory uncertainties, trial execution, and commercialization challenges. Overall, Scholar Rock represents a high-risk, high-reward opportunity driven by upcoming pivotal data.

Upcoming Catalysts (preview)

• Q2 2026Phase 3 TOPAZ trial data for apitegromab in SMA65% success
• Q4 2026BLA submission for apitegromab in SMA60% success
• Q1 2027Initial Phase 1 data for SRK-439 in myelofibrosis40% success